GlassScriptPhysician profile
Carlos Franco
NPI 1205044492
$8,035.79
in general payments reported to CMS, 2019-2025
28 companies · $1,742 in 2025
The $1,742 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,051 · 2022: $1,038 · 2023: $2,239 · 2024: $1,966 · 2025: $1,742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,923 · Education: $18.09 · Travel and Lodging: $5.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,923.35 |
| Education | $18.09 |
| Travel and Lodging | $5.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,224.80 | 2022-2025 | Biktarvy, Vemlidy, Yeztugo |
| Viiv Healthcare Company | $1,400.12 | 2022-2025 | Dovato, Apretude, Cabenuva |
| Novo Nordisk INC | $671.85 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $553.76 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $537.14 | 2021-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $394.74 | 2021-2024 | Delstrigo, Pifeltro, Isentress |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.40 | 2021-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.37 | 2021-2025 | Xifaxan |
| Janssen Biotech, INC. | $239.15 | 2023 | Symtuza |
| Abbvie INC. | $195.64 | 2024-2025 | |
| Emd Serono, INC. | $182.40 | 2023-2025 | Serostim |
| Janssen Pharmaceuticals, INC | $162.81 | 2022 | |
| Janssen Scientific Affairs, LLC | $161.71 | 2023 | Symtuza |
| Corcept Therapeutics | $126.04 | 2024-2025 | Korlym |
| Amarin Pharma, INC. | $124.17 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $116.17 | 2023-2025 | Cologuard Collection Kit |
| Theratechnologies INC. | $67.12 | 2023-2024 | Trogarzo, Egrifta |
| Dexcom, INC. | $60.98 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $56.99 | 2023 | |
| Paratek Pharmaceuticals, INC. | $55.70 | 2023-2025 | Nuzyra |
| Abbott Laboratories | $50.15 | 2021-2022 | |
| Glaxosmithkline, LLC. | $49.10 | 2022-2025 | Arexvy, Bexsero, Shingrix |
| Exeltis, USA INC. | $24.17 | 2023 | Slynd |
| Shionogi INC | $23.06 | 2025 | Fetroja |
| Biohaven Pharmaceuticals, INC. | $21.44 | 2021 | |
| Phadia US INC. | $19.07 | 2025 | Immunocap |
| Alkermes, INC. | $17.10 | 2023 | Vivitrol |
| Astrazeneca Pharmaceuticals LP | $14.64 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Franco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.